Contents Link Navigation Link
TECHNOLOGY

Targeting, Attacking, and Eradicating Cancers®

SOLVE®

Targeting, Attacking, and Eradicating Cancers®

Mechanism of Action
1. Direct Cell Lysis
2. Adaptive Immune Response
3. Vascular Shutdown
3. Vascular Shutdown
3-prolonged attack on cancer : direct cell lysis with replication and spread, immune activation, antivascular
  • Tumor selective intratumoral replication of the virus leads to lysis of the infected cancer cell and spread to adjacent cancer cells
  • Induction of tumor-specific cytotoxic T-lymphocytes and “arming” for expression of therapeutic transgene products (e.g. GM-CSF) enhance immune response to the tumor
  • Blood flow to tumors can be blocked following intratumoral replication and spread

Key References:Kirn et al, Nature Reviews Cancer 2009 | Breitbach et al, Nature 2011 | Breitbach et al, Cancer Res 2013 | Kim et al, Science Transl Med 2013

Mechanism of Action (Pexa-Vec, JX-594)
Lead Clinical Candidate Pexa-Vec (JX-594)
PEXA-VEC (JX-594)

Clinical-stage oncolytic immunotherapy demonstrating both IT and IV delivery to tumors and induction of cancer specific antibodies

JX-594
  • Pexa-Vec(pexastimogene devacirepvec, or “JX-594”) is a modified vaccinia vaccine (Wyeth strain)
  • “Attenuation” via TK (thymidine kinase) gene inactivation--provides tumor selectivity & safety
  • GM-CSF added to activate systemic immunity (dendritic cell maturation, T cell stimulant)
  • LacZ as a marker gene